Assessment
mepolizumab
Hypereosinophilic syndrome (HES) without identifiable non-haematological secondary cause, inadequately controlled
- Modules
- IQWiG assessments · G-BA decisions
- Connections
- 2
Connected evidence
2 relationsAssessment
Hypereosinophilic syndrome (HES) without identifiable non-haematological secondary cause, inadequately controlled
Connected evidence
2 relations